الصفحة الرئيسية>>Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

رقم الكتالوجGC90558

مضاد للـ MBP

Products are for research use only. Not for human use. We do not sell to patients.

Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt) التركيب الكيميائي

الحجم السعر المخزون الكميّة
1 mg
40٫00
متوفر
5 mg
180٫00
متوفر
10 mg
317٫00
متوفر
25 mg
695٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Myelin basic protein (MBP) peptide antagonist is a synthetic peptide antagonist against the multiple sclerosis (MS) autoantigen MBP.1 MBP peptide antagonist binds to the immunomodulatory region of MBP, corresponding to residues 85-99 and inhibits MBP binding to human HLA-DR2 in a concentration-dependent manner. It inhibits the production of IL-2 in T cell bridoma cells expressing an MBP (85-99)-specific T cell receptor derived from a patient with multiple sclerosis. MBP peptide antagonist also delays MBP (85-99)-induced experimental autoimmune encephalomyelitis (EAE) onset and reduces EAE symptom severity in double-transgenic humanized mice expressing human HLA-DR2 and MBP (85-99)-specific T cell receptor antigen in a model of MS when administered at a dose of 100 µg/animal.

مراجعات

Review for Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.